Tesamorelin FAQ — Questions Answered | Real Peptides

Tesamorelin FAQ — Questions Answered | Real Peptides

Tesamorelin generates more questions than most peptides because its mechanism contradicts what people assume about fat loss compounds. It doesn't suppress appetite like semaglutide, doesn't increase thermogenesis like clenbuterol, and doesn't block nutrient absorption like orlistat. Instead, it amplifies growth hormone-releasing hormone (GHRH) signaling to restore pulsatile GH secretion. A pathway that affects visceral adipose tissue specifically, not subcutaneous fat. That specificity creates confusion about what it does, who it works for, and how to use it correctly.

This tesamorelin FAQ covers the most common points of confusion we've encountered working with researchers and clinicians: reconstitution protocols that preserve peptide integrity, dosing schedules that match published trial data, side effect management strategies, and the difference between tesamorelin and other growth hormone secretagogues like sermorelin or ipamorelin. We'll also address storage requirements, injection site rotation, what happens when you stop using it, and whether combining it with other compounds amplifies or diminishes the effect.

What is tesamorelin and how does it work for fat reduction?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids. The first 29 match endogenous GHRH, with a trans-3-hexenoic acid group attached to enhance stability and extend half-life. It binds to GHRH receptors on anterior pituitary somatotrophs, triggering the release of endogenous growth hormone in a pulsatile pattern that mirrors natural physiological secretion. Unlike exogenous GH administration, tesamorelin preserves feedback loops. The hypothalamic-pituitary axis remains responsive to somatostatin, preventing the receptor desensitization seen with continuous GH exposure.

The mechanism hasn't been diluted for marketing. Tesamorelin was FDA-approved in 2010 specifically for reducing excess abdominal fat in HIV-associated lipodystrophy. The GHRH receptor activation increases lipolysis in visceral adipocytes through hormone-sensitive lipase upregulation, targeting intra-abdominal fat deposits that respond poorly to caloric restriction or exercise. This isn't speculative. Phase 3 trials published in The Lancet and the Journal of the American Medical Association demonstrated mean visceral adipose tissue reductions of 15.2% at 26 weeks compared to 4.4% with placebo.

Here's what separates tesamorelin from GH secretagogues like Ipamorelin or GHRP-6: it acts directly on GHRH receptors rather than ghrelin receptors. That distinction matters because GHRH signaling produces physiological GH pulses without the appetite stimulation or cortisol elevation common to ghrelin-pathway agonists. The result is targeted visceral fat reduction with minimal impact on subcutaneous adipose tissue. Which explains why patients often see waist circumference changes before scale weight drops.

Reconstitution and Storage: Where Most Protocols Fail

Tesamorelin arrives as lyophilised powder requiring reconstitution with bacteriostatic water before subcutaneous injection. The reconstitution step is where most handling errors occur. Not because the process is complex, but because the margin for error is smaller than people assume. Tesamorelin's 44-amino-acid chain is vulnerable to shear forces, temperature excursions, and pH shifts that denature the peptide structure irreversibly.

Before reconstitution, store lyophilised tesamorelin at −20°C (standard freezer temperature). The powder remains stable at this temperature for 18–24 months when properly sealed. Room temperature exposure during shipping. Up to 25°C for 48–72 hours. Doesn't significantly degrade lyophilised peptides, but prolonged ambient storage does. If you receive a shipment that feels warm or wasn't packed with ice packs, contact the supplier immediately rather than assuming it's fine.

Reconstitution protocol: Allow the vial to reach room temperature naturally (15–20 minutes) before adding bacteriostatic water. Add 2–3 mL of bacteriostatic water by injecting it slowly down the inside wall of the vial. Never directly onto the lyophilised cake. The most common mistake? Shaking the vial to dissolve the powder. Don't. Swirl gently or let it sit for 3–5 minutes until fully dissolved. Vigorous shaking introduces air bubbles and mechanical stress that fragment peptide bonds.

Once reconstituted, tesamorelin must be refrigerated at 2–8°C and used within 28 days. The half-life of reconstituted tesamorelin in solution is approximately 4–6 hours at room temperature, which is why refrigeration is non-negotiable. Temperature excursions above 8°C. Even brief ones. Accelerate degradation. A single instance of leaving reconstituted tesamorelin on the counter for two hours doesn't render it completely inactive, but repeated exposure adds up. If potency matters, treat the 2–8°C range as absolute.

Storage tip from our experience with research teams: label each vial with reconstitution date and discard after 28 days regardless of remaining volume. Visual clarity isn't a potency indicator. Degraded peptides often remain clear and colourless. Don't extend usage based on appearance alone.

Dosing Schedules and Injection Protocols

The FDA-approved dosing for tesamorelin in HIV-associated lipodystrophy is 2 mg subcutaneously once daily, administered in the abdomen. That's the baseline derived from clinical trials including the COSMIX and REALITY studies, both published in peer-reviewed journals. Off-label use often mirrors this protocol, though some clinicians titrate starting doses to 1 mg daily for the first week to assess tolerance before increasing to the full 2 mg maintenance dose.

Tesamorelin has a plasma half-life of 26–38 minutes, which seems counterintuitive for a once-daily medication. The short half-life is intentional. It triggers an acute GH pulse that subsides within hours, mimicking the body's natural pulsatile secretion pattern rather than maintaining constant elevation. This pulsatility is what differentiates GHRH agonists from continuous GH infusion, preserving receptor sensitivity and feedback regulation.

Injection timing: Most protocols specify evening administration, 30–60 minutes before bedtime. The rationale is physiological. Endogenous GH secretion peaks during deep sleep, and exogenous GHRH administration before sleep augments this natural nocturnal pulse. Morning dosing isn't contraindicated, but evening administration aligns with circadian GH rhythms and may enhance efficacy. Clinical trials used consistent evening dosing, so deviating from that schedule moves you outside the evidence base.

Injection site rotation is critical for minimizing lipohypertrophy (localized fat accumulation at injection sites). Rotate injection sites within the abdominal region. Divide the abdomen into quadrants and rotate clockwise or in a systematic pattern. Injecting the same site repeatedly over days or weeks causes nodule formation and reduces absorption consistency. The abdomen is preferred over thighs or deltoids because subcutaneous absorption kinetics in abdominal tissue match the pharmacokinetic profiles used in clinical trials.

One nuance most guides omit: the injection should be at least 2 inches away from the navel. The umbilical region has denser connective tissue and less predictable blood flow, which can reduce absorption and increase injection site reactions. Mark a 2-inch radius around your navel and avoid that zone entirely.

Combining tesamorelin with other peptides. Particularly CJC1295 Ipamorelin or Sermorelin. Requires understanding receptor mechanisms. Tesamorelin and sermorelin both target GHRH receptors, so stacking them doesn't amplify the effect; it just increases receptor saturation without proportional GH release. Ipamorelin, by contrast, acts on ghrelin receptors, creating a synergistic dual-pathway stimulation. The Tesamorelin Ipamorelin Growth Hormone Stack offered by Real Peptides uses this complementary mechanism. GHRH receptor activation via tesamorelin plus ghrelin receptor activation via ipamorelin produces greater GH output than either compound alone.

Side Effects, Contraindications, and Adverse Event Management

The most common adverse events reported in tesamorelin clinical trials include injection site reactions (erythema, pruritus, irritation) in 20–35% of participants, arthralgia (joint pain) in 12–18%, and peripheral edema in 8–12%. These effects are dose-dependent and typically mild to moderate in severity. Injection site reactions usually resolve within 48–72 hours and decrease in frequency with continued use. Rotating injection sites significantly reduces their occurrence.

Arthralgia associated with tesamorelin is mechanistically distinct from inflammatory joint pain. Growth hormone increases fluid retention in joint spaces and periarticular tissues, which can cause transient stiffness or discomfort. This isn't joint damage. It's fluid redistribution. The effect usually peaks during the first 4–8 weeks of therapy and diminishes as the body adapts to elevated GH levels. If arthralgia is severe or persistent beyond 12 weeks, dose reduction or temporary discontinuation is appropriate.

Peripheral edema (swelling in hands, feet, or ankles) follows the same fluid retention mechanism. Mild edema is common and self-limiting; severe edema accompanied by shortness of breath, rapid weight gain (more than 2 kg in 48 hours), or visual changes requires immediate medical evaluation. These could indicate more serious complications including carpal tunnel syndrome or elevated intracranial pressure. Both documented in GH-excess states.

Glucose metabolism changes warrant attention. Tesamorelin increases insulin-like growth factor 1 (IGF-1) levels, which can reduce insulin sensitivity and elevate fasting glucose. In the COSMIX trial, mean fasting glucose increased by 3–5 mg/dL in the tesamorelin group versus placebo. For individuals with prediabetes or type 2 diabetes, this effect may worsen glycemic control. Baseline HbA1c and fasting glucose should be measured before starting tesamorelin, with follow-up testing at 12 weeks and then every 6 months. If HbA1c increases by more than 0.5%, discontinuation should be considered.

Absolute contraindications: active malignancy, history of pituitary tumor or cranial surgery disrupting pituitary function, and hypersensitivity to tesamorelin or any component of the formulation. Tesamorelin stimulates cell proliferation through IGF-1 pathways, which makes it inappropriate for anyone with active cancer or recent cancer history (within 5 years). Pregnancy is also a contraindication. Tesamorelin is classified as FDA Pregnancy Category X due to unknown fetal effects.

Here's the honest answer about long-term safety: tesamorelin has been studied for up to 52 weeks in controlled trials, with extension studies reaching 78 weeks. Beyond that timeframe, data is observational rather than controlled. The longest-term data comes from HIV lipodystrophy cohorts, where continuous use for 2–3 years showed sustained visceral fat reduction without significant adverse event accumulation. That said, most off-label use cycles tesamorelin rather than using it continuously for years. Typical protocols involve 3–6 month cycles followed by 1–2 month washout periods.

Tesamorelin FAQ: Dosing, Mechanism, and Research Use Comparison

The table below compares tesamorelin to other growth hormone secretagogues based on mechanism, half-life, dosing frequency, and primary research applications. Understanding these distinctions clarifies why tesamorelin produces different outcomes than compounds often mentioned alongside it.

Tesamorelin

GHRH receptor agonist

26–38 minutes

2 mg SC daily (evening)

Visceral adipose tissue reduction in lipodystrophy

Targets visceral fat specifically via pulsatile GH release; FDA-approved for HIV lipodystrophy; minimal appetite effects

Sermorelin

~10 minutes

200–500 mcg SC daily

Anti-aging and body composition research

Shorter half-life than tesamorelin; similar mechanism but less stable; often used in longevity protocols

Ipamorelin

Ghrelin receptor agonist

~2 hours

200–300 mcg SC 2–3× daily

GH release without cortisol/prolactin elevation

Synergistic with GHRH agonists; minimal side effects; does not elevate cortisol like GHRP-6

CJC-1295 (with DAC)

6–8 days

2 mg SC weekly

Sustained GH elevation research

Long half-life allows weekly dosing; higher risk of desensitization; less physiological pulsatility

MK-677 (Ibutamoren)

Ghrelin receptor agonist (oral)

4–6 hours

10–25 mg oral daily

Oral GH secretagogue research

Oral bioavailability; increases appetite significantly; elevates cortisol and prolactin more than ipamorelin

Tesamorelin's specificity for visceral adipose tissue makes it the preferred choice when central obesity is the primary concern. Combining it with ipamorelin, as in the Tesamorelin Ipamorelin Growth Hormone Stack, leverages dual receptor pathways without redundancy. MK 677, by contrast, offers oral convenience but comes with appetite stimulation that can counteract fat loss efforts. A trade-off worth considering based on research objectives.

Key Takeaways

Tesamorelin is a 44-amino-acid GHRH analogue that stimulates pulsatile growth hormone release, targeting visceral adipose tissue specifically rather than overall body fat.

Clinical trials demonstrated 15.2% mean visceral fat reduction at 26 weeks in HIV lipodystrophy patients, compared to 4.4% with placebo, published in The Lancet.

Store lyophilised tesamorelin at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to maintain potency.

Standard dosing is 2 mg subcutaneously once daily in the evening, 30–60 minutes before bedtime, to align with natural nocturnal GH secretion patterns.

Common side effects include injection site reactions (20–35%), arthralgia (12–18%), and mild peripheral edema. Most resolve within 4–8 weeks as the body adapts.

Tesamorelin increases IGF-1 and may elevate fasting glucose by 3–5 mg/dL; monitor HbA1c at baseline, 12 weeks, and every 6 months in prediabetic or diabetic individuals.

Combining tesamorelin with ipamorelin creates synergistic GH release through complementary GHRH and ghrelin receptor pathways without receptor desensitization.

What If: Tesamorelin Scenarios

What If I Miss a Dose of Tesamorelin?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your scheduled injection time. If more than 12 hours have passed, skip the missed dose and resume your regular schedule the following evening. Do not double-dose to compensate. Tesamorelin's mechanism relies on pulsatile GH release rather than steady-state blood levels, so missing a single dose doesn't set back progress significantly. Consistency matters more than perfection. Missing one dose per week has negligible impact on 26-week visceral fat outcomes, but missing 3–4 doses weekly reduces efficacy proportionally.

What If My Reconstituted Tesamorelin Looks Cloudy or Has Particles?

Discard it immediately. Properly reconstituted tesamorelin should be clear and colourless. Cloudiness indicates protein aggregation, and visible particles suggest contamination or degradation. Neither is salvageable through filtration or additional dilution. The peptide structure is already compromised. This most commonly occurs when bacteriostatic water is added too forcefully, when the vial is shaken rather than swirled, or when the solution experiences temperature cycling. Don't inject cloudy peptide solutions under any circumstance. The risk of injection site reactions increases, and potency is unreliable.

What If I Want to Stop Using Tesamorelin — Will Visceral Fat Return?

Gradual discontinuation isn't necessary because tesamorelin doesn't suppress endogenous GHRH production the way exogenous testosterone suppresses natural testosterone. You can stop abruptly without tapering. Clinical trial data shows that visceral adipose tissue begins to re-accumulate within 12–16 weeks after discontinuation, though the rate varies based on diet, activity level, and metabolic health. By 26 weeks post-discontinuation, approximately 60–70% of the visceral fat lost during treatment returns if no other interventions are implemented. This isn't rebound. It's regression to baseline physiology. Tesamorelin corrects a hormonal signal (insufficient pulsatile GH); removing that signal allows the original metabolic state to reassert itself.

What If Tesamorelin Causes Severe Joint Pain That Doesn't Resolve After 8 Weeks?

Reduce the dose to 1 mg daily for 2–4 weeks to assess whether symptoms improve. If arthralgia persists at the reduced dose or worsens, discontinue tesamorelin and consult the prescribing clinician. Persistent joint pain beyond 12 weeks at therapeutic doses may indicate underlying conditions exacerbated by GH elevation. Including undiagnosed osteoarthritis, rotator cuff pathology, or carpal tunnel syndrome. Growth hormone increases synovial fluid volume and can elevate intra-articular pressure, which amplifies symptoms in joints with pre-existing structural damage. In our experience supporting research teams, severe persistent arthralgia occurs in fewer than 5% of users, but when it does occur, continuing therapy rarely produces benefit that outweighs discomfort.

The Clinical Truth About Tesamorelin

Here's the honest answer: tesamorelin won't give you abs if you're 25% body fat. It reduces visceral adipose tissue. The metabolically active fat surrounding internal organs. Not the subcutaneous layer you can pinch. That distinction is critical because marketing often conflates the two. Visceral fat reduction improves metabolic markers (insulin sensitivity, triglycerides, inflammatory cytokines) and reduces waist circumference, but it doesn't create visible muscle definition or reduce love handles. If your goal is aesthetic fat loss, tesamorelin alone won't deliver what tirzepatide or a structured caloric deficit would.

The evidence is clear: tesamorelin works exceptionally well for the specific indication it was designed for. Reducing excess abdominal visceral fat in populations with lipodystrophy or GH insufficiency. Phase 3 data is unambiguous on this point. But extending that efficacy to general-population fat loss is speculative. Most people seeking fat loss don't have pathological visceral adiposity; they have normal-range visceral fat and excess subcutaneous fat. Tesamorelin won't meaningfully affect the latter.

Another reality rarely mentioned: tesamorelin is expensive. Brand-name Egrifta costs $3,000–$5,000 monthly in the absence of insurance coverage. Compounded tesamorelin from licensed 503B facilities reduces that cost to $200–$600 monthly, which is still higher than most peptide protocols. The cost-benefit calculation depends entirely on whether visceral fat is your primary concern and whether you've exhausted more accessible interventions like GLP-1 agonists, resistance training, or dietary modification.

Finally. Tesamorelin is not a longevity peptide in the way Epithalon or Thymalin are researched for anti-aging. It targets a specific metabolic dysfunction (visceral adiposity driven by insufficient GH pulsatility). If you don't have that dysfunction, the marginal benefit is minimal. The peptide space is crowded with compounds marketed as universal solutions. Tesamorelin isn't one of them. Use it for what it does exceptionally well, and pair it with interventions that address what it doesn't.

The tesamorelin FAQ most researchers need isn't 'does it work?'. The clinical trial data answers that definitively. The real question is whether your specific research objective aligns with its validated mechanism, and whether the cost and administration burden are justified by outcomes other interventions can't achieve. For visceral adiposity reduction in populations where GH pulsatility is impaired, tesamorelin remains one of the most evidence-backed options available in 2026. For general fat loss, subcutaneous adipose reduction, or aesthetic goals, it's not the first-line choice.

Real Peptides provides research-grade Tesamorelin Peptide with full amino acid sequencing verification and third-party purity testing. Every batch is synthesized to pharmaceutical-grade standards and shipped with proper cold chain handling to preserve peptide integrity from production to your lab. Whether you're exploring tesamorelin individually or as part of a growth hormone stack, our commitment to precision and transparency ensures the compounds you're working with match the specifications your research demands.

Frequently Asked Questions

Tesamorelin and sermorelin both bind to GHRH receptors on pituitary somatotrophs to stimulate growth hormone release, but tesamorelin has a significantly longer plasma half-life (26–38 minutes vs ~10 minutes for sermorelin) due to the trans-3-hexenoic acid modification on its structure. This extended half-life produces more sustained GH pulses and allows once-daily dosing, whereas sermorelin’s rapid degradation often requires multiple daily injections. Clinical evidence for visceral fat reduction is stronger for tesamorelin, with FDA approval specifically for HIV-associated lipodystrophy based on Phase 3 trials showing 15.2% mean visceral adipose tissue reduction at 26 weeks.

Tesamorelin can be used in individuals with prediabetes or type 2 diabetes, but it requires close glycemic monitoring because GH elevation increases IGF-1 levels and can reduce insulin sensitivity. Clinical trials showed mean fasting glucose increases of 3–5 mg/dL in tesamorelin groups versus placebo, and some participants experienced HbA1c elevations of 0.5% or more. Baseline HbA1c and fasting glucose should be measured before starting therapy, with follow-up testing at 12 weeks and every 6 months thereafter. If HbA1c rises by more than 0.5%, discontinuation or dose reduction should be considered in consultation with a prescribing clinician.

Brand-name Egrifta (FDA-approved tesamorelin) typically costs $3,000–$5,000 per month without insurance coverage, whereas compounded tesamorelin from licensed 503B outsourcing facilities ranges from $200–$600 monthly depending on dosage and supplier. Compounded tesamorelin contains the same 44-amino-acid active molecule as Egrifta but is prepared by state-licensed compounding pharmacies rather than the branded manufacturer. The cost difference is substantial, but compounded versions are not FDA-approved as finished drug products — they’re produced under USP standards and state pharmacy board oversight, which is a different regulatory pathway than the full FDA approval Egrifta holds.

Measurable visceral adipose tissue reduction typically becomes evident at 12–16 weeks based on imaging studies (CT or MRI), with peak effects observed at 26 weeks in the COSMIX and REALITY trials. Waist circumference changes may be noticeable earlier — some individuals report reductions of 1–2 cm within 8 weeks — but these correlate with visceral fat loss rather than subcutaneous fat changes. The timeline depends on baseline visceral adiposity, adherence to daily dosing, and concurrent lifestyle factors including diet and resistance training. Clinical trials used consistent daily dosing without interruption, so sporadic use or frequent missed doses will extend the time to measurable outcomes.

Controlled trial data for tesamorelin extends to 52 weeks in primary studies and 78 weeks in extension studies, with observational data from HIV lipodystrophy cohorts showing continuous use for 2–3 years without significant adverse event accumulation. The primary long-term concerns are glucose metabolism changes (persistent insulin resistance or progression to type 2 diabetes in susceptible individuals), joint complications from chronic fluid retention, and theoretical cancer risk from sustained IGF-1 elevation — though no causal link has been established in clinical populations. Most protocols cycle tesamorelin rather than using it continuously for years, with 3–6 month treatment periods followed by 1–2 month washout intervals to allow metabolic parameters to normalize.

Combining tesamorelin with GLP-1 receptor agonists like tirzepatide or semaglutide is mechanistically plausible because they target different pathways — tesamorelin increases GH-mediated lipolysis in visceral adipocytes, while GLP-1 agonists reduce appetite and slow gastric emptying to create a caloric deficit. No controlled trials have evaluated this specific combination, so safety and efficacy data are observational rather than evidence-based. The primary consideration is glucose metabolism: both tesamorelin and GLP-1 agonists affect insulin sensitivity, though in opposite directions — tesamorelin may reduce it slightly while GLP-1 agonists improve it. Monitoring fasting glucose and HbA1c is essential if combining these compounds.

Visceral adipocytes express higher densities of growth hormone receptors and beta-adrenergic receptors compared to subcutaneous adipocytes, making them more responsive to GH-mediated lipolysis. When tesamorelin stimulates pulsatile GH release, the resulting hormone-sensitive lipase activation preferentially targets visceral fat depots because they have the receptor infrastructure to respond. Subcutaneous fat, by contrast, has lower GH receptor density and higher alpha-adrenergic receptor activity, which inhibits lipolysis. This differential receptor expression is why visceral fat reduces significantly (15.2% mean reduction at 26 weeks in clinical trials) while subcutaneous fat shows minimal change — the biological machinery in each fat depot responds differently to the same hormonal signal.

No mandatory washout period is required when switching from tesamorelin to another growth hormone secretagogue because tesamorelin has a plasma half-life of only 26–38 minutes and doesn’t suppress endogenous GHRH production or pituitary function. You can begin an alternative compound like sermorelin, ipamorelin, or CJC-1295 the day after your final tesamorelin dose without physiological conflict. The decision to switch should be based on outcome goals rather than tolerance concerns — if visceral fat reduction has plateaued or if cost is prohibitive, transitioning to a less expensive secretagogue may be appropriate, but the specific visceral adipose-targeting effect of tesamorelin may not be replicated by compounds with different receptor profiles.

Yes, systematic injection site rotation is essential to prevent lipohypertrophy (localized fat accumulation) and maintain consistent absorption. Divide the abdominal region into quadrants and rotate injection sites in a systematic pattern, avoiding the same site within 7–10 days. Injections should be at least 2 inches away from the navel because umbilical tissue has denser connective structures and less predictable blood flow, which can reduce absorption and increase injection site reactions. Repeatedly injecting the same site causes nodule formation, skin thickening, and reduced peptide absorption — problems that develop gradually over weeks but significantly impair efficacy once established.

Women can use tesamorelin for visceral adiposity reduction under medical supervision, and clinical trials included female participants in both HIV lipodystrophy studies and general population research. However, tesamorelin is classified as FDA Pregnancy Category X, meaning it is absolutely contraindicated during pregnancy due to unknown fetal effects — women of childbearing potential should use reliable contraception during treatment. The GH-elevating mechanism does not interfere with estrogen or progesterone pathways, so tesamorelin does not disrupt menstrual cycles or reproductive function in the way anabolic steroids might, but the lack of long-term reproductive safety data requires caution in women planning pregnancy within 6–12 months.

Persistent nausea or gastrointestinal symptoms with tesamorelin are uncommon because it acts on pituitary GHRH receptors rather than gut-based incretin pathways like GLP-1 agonists do. If GI symptoms occur, they’re more likely related to injection technique, contamination of the reconstituted solution, or coincidental illness rather than tesamorelin’s pharmacological action. Evaluate injection hygiene (alcohol swab prep, sterile needle use, proper vial handling) and inspect the reconstituted solution for cloudiness or particles. If symptoms persist beyond 72 hours despite proper technique and clear solution, discontinue use and consult the prescribing clinician — persistent GI symptoms suggest either contamination or an unrelated medical issue rather than a direct drug effect.

There is no acute rebound effect when stopping tesamorelin because it doesn’t suppress appetite or alter ghrelin signaling the way GLP-1 receptor agonists do. Visceral adipose tissue does gradually re-accumulate after discontinuation — clinical data shows approximately 60–70% of lost visceral fat returns within 26 weeks post-treatment if no other interventions are maintained. This is regression to baseline physiology rather than rebound. Tesamorelin corrects a hormonal insufficiency (reduced GH pulsatility); removing that correction allows the metabolic state to revert. Maintaining visceral fat loss after stopping tesamorelin requires addressing the underlying factors that caused accumulation in the first place — typically insulin resistance, chronic caloric surplus, or sedentary behavior.